Re Review on Antimicrobial Resistance

RNS Number : 6582Y

Redx Pharma plc

19 May 2016

 

19 May 2016

AIM: REDX

REDX PHARMA PLC

("Redx" or "the Group")

Redx welcomes Final Recommendations from Review on Antimicrobial Resistance

Redx, the drug discovery and development company, today welcomes the publication of the final paper prepared by the Review on Antimicrobial Resistance, chaired by Lord Jim O'Neill. This paper sets out the Review's final recommendations to tackle the problem of antimicrobial resistance ("AMR") at a global level.

The Report notes that while the magnitude of the antimicrobial resistance threat has now been accepted, policymakers and governments need to implement solutions in order to prevent putting an estimated ten million lives per year and cumulative 100 trillion USD of economic output at risk by 2050.

Redx fully supports the 10 point plan set out in the Review, especially the recommendations aimed at increasing the number of effective antimicrobial drugs. This is a task that Redx has been working hard to achieve and the Group therefore welcomes the Review's proposals to establish a global innovation fund for early-stage and non-commercial research and to offer better incentives to promote investment for new drugs and improve existing ones.

The report can be found on the following link: http://amr-review.org/Publications

Neil Murray, Chief Executive of Redx, commented:

"We welcome the proposals put forward by the Review on Antimicrobial Resistance. We are now at a critical point in dealing with an unfolding health catastrophe and without decisive action, AMR will result in a devastating loss of both human lives and economic prosperity.

The Review marks an important step forward, and we see significant potential for the Innovation Fund and new commercialisation models. It is now the collective responsibility of all members of society to ensure these changes are implemented to avoid the consequences of antibiotics failing.

We would like to thank the Review on Antimicrobial Resistance and especially Chairman Jim O'Neill for bringing global awareness to this critical issue. We urge policymakers and governments around the world to heed the call for action and take the necessary steps to implement solutions to tackle this looming crisis before it is too late."

For further information, please contact:

Redx Pharma Plc	T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
KTZ Communications	T: 020 3178 6378
Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary (patent‑protected) drug programs. Six proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.

About the Review on Antimicrobial Resistance

The UK Prime Minister commissioned the Review on Antimicrobial Resistance to address the growing global problem of drug-resistant infections. It is chaired by Lord Jim O'Neill and supported by the Wellcome Trust and UK Government, but operates and speaks with full independence from both.

 

END

 

 

NRAAKFDBABKDOPD